U.S., April 15 -- ClinicalTrials.gov registry received information related to the study (NCT07527325) titled 'Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma' on April 07.
Brief Summary: This is a phase II, open label clinical trial determining efficacy of Fianlimab in combination with Cemiplimab in subjects with Melanoma. These are subjects who will have surgery to remove their cancer.
Study Start Date: April 30
Study Type: INTERVENTIONAL
Condition:
Melanoma (Skin)
Intervention:
DRUG: Fianlimab
Given IV
DRUG: Cemiplimab
Given IV
Recruitment Status: NOT_YET_RECRUITING
Sponsor: University of California, Irvine
Information provided by (Responsible Party): Warren Chow, University of California, Irvine
Disclaimer: Curate...